Banque Cantonale Vaudoise’s Faeth Therapeutics FTH Stock Holding History

Banque Cantonale Vaudoise’s Portfolio FTH Stock Details FTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-195	Closed	-$2K	–	987
2024 Q2	$2K	Hold	195	–	–	﹤0.01%	978
2024 Q1	$4K	Hold	195	–	–	﹤0.01%	954
2023 Q4	$3K	Hold	195	–	–	﹤0.01%	990
2023 Q3	$3K	Hold	195	–	–	﹤0.01%	1158
2023 Q2	$4K	Hold	195	–	–	﹤0.01%	1141
2023 Q1	$6K	Hold	195	–	–	﹤0.01%	1134
2022 Q4	$6K	Hold	195	–	–	﹤0.01%	1134
2022 Q3	$6K	Hold	195	–	–	﹤0.01%	1180
2022 Q2	$9K	Hold	195	–	–	﹤0.01%	1196
2022 Q1	$9K	Buy	195 +150	+333%	+$11.9K	﹤0.01%	1217
2021 Q4	$5K	Buy	45 +30	+200%	+$4.48K	﹤0.01%	1263
2021 Q3	$3K	Hold	15	–	–	﹤0.01%	1244
2021 Q2	$3K	Buy	+15	New	+$3.71K	﹤0.01%	1225

Other funds holding FTH

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Banque Cantonale Vaudoise's FTH Position: Q3 2024 in Review

Banque Cantonale Vaudoise sold out of Faeth Therapeutics (FTH) in Q3 2024, closing a stake of 195 shares — an estimated $2K sold.

Banque Cantonale Vaudoise first reported a position in FTH in Q2 2021 and held it in 13 quarters. The position peaked at $9K in Q2 2022. 19 funds tracked by Wall St. Rank hold FTH as of Q3 2024.

Banque Cantonale Vaudoise reported no remaining Faeth Therapeutics position as of Q3 2024 after selling out during the quarter.
Banque Cantonale Vaudoise sold 195 Faeth Therapeutics shares in Q3 2024, an estimated $2K.
Banque Cantonale Vaudoise first reported a position in Faeth Therapeutics in Q2 2021 and held it in 13 quarters.
Banque Cantonale Vaudoise's Faeth Therapeutics position peaked at $9K in Q2 2022.
19 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q3 2024.

Based on Banque Cantonale Vaudoise's 13F filing for Q3 2024, filed 8 Nov 2024.